Generic placeholder image

Current Drug Targets


ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Review Article

MiRNA, a New Treatment Strategy for Pulmonary Fibrosis

Author(s): Yanhong Liu, Hongguang Nie*, Yan Ding, Yapeng Hou, Kejun Mao and Yong Cui

Volume 22 , Issue 7 , 2021

Published on: 28 September, 2020

Page: [793 - 802] Pages: 10

DOI: 10.2174/1874609813666200928141822

Price: $65


Pulmonary fibrosis (PF) is the most common chronic, progressive interstitial lung disease, mainly occurring in the elderly, with a median survival of 2-4 years after diagnosis. Its high mortality rate attributes to the delay in diagnosis due to its generic symptoms, and more importantly, to the lack of effective treatments. MicroRNAs (miRNAs) are a class of small non-coding RNAs that are involved in many essential cellular processes, including extracellular matrix remodeling, alveolar epithelial cell apoptosis, epithelial-mesenchymal transition, etc. We summarized the dysregulated miRNAs in TGF-β signaling pathway-mediated PF in recent years with dual effects, such as anti-fibrotic let-7 family and pro-fibrotic miR-21 members. Therefore, this review will set out the latest application of miRNAs to provide a new direction for PF treatment.

Keywords: Pulmonary fibrosis, microRNAs, transforming growth factor-β, extracellular matrix, epithelial-mesenchymal transition, pro-fibrotic.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy